WO2002024228A1 - Méthode de régulation de la formation d'ostéoclastes - Google Patents

Méthode de régulation de la formation d'ostéoclastes Download PDF

Info

Publication number
WO2002024228A1
WO2002024228A1 PCT/JP2001/008244 JP0108244W WO0224228A1 WO 2002024228 A1 WO2002024228 A1 WO 2002024228A1 JP 0108244 W JP0108244 W JP 0108244W WO 0224228 A1 WO0224228 A1 WO 0224228A1
Authority
WO
WIPO (PCT)
Prior art keywords
osteoclast formation
signal
type ifn
ifn
formation
Prior art date
Application number
PCT/JP2001/008244
Other languages
English (en)
Japanese (ja)
Inventor
Tadatsugu Taniguchi
Hiroshi Takayanagi
Kozo Nakamura
Original Assignee
Center For Advanced Science And Technology Incubation, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center For Advanced Science And Technology Incubation, Ltd. filed Critical Center For Advanced Science And Technology Incubation, Ltd.
Priority to AU2001288094A priority Critical patent/AU2001288094A1/en
Priority to JP2002528298A priority patent/JPWO2002024228A1/ja
Publication of WO2002024228A1 publication Critical patent/WO2002024228A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Cette invention concerne une méthode de régulation d'un signal de formation d'ostéoclastes. On a constaté que le processus de formation d'ostéoclastes pouvait être inhibé par activation de la transduction du signal IFN type II. L'activation dudit signal permet de rétro-réguler l'expression de la protéine TRAF6 induite par RANKL et, par là même, d'inhiber la formation d'ostéoclastes. IFN type II (IFN-η) a pour effet d'inhiber selon la dose la formation des ostéoclastes. Il apparaît qu'un signal induit par Sta I est important dans l'inhibition de la formation d'ostéoclastes par IFN type II. On dispose ainsi d'une nouvelle stratégie thérapeutique contre des maladies liées à des déréglements osseux en rapport avec l'arthrite auto-immune.
PCT/JP2001/008244 2000-09-21 2001-09-21 Méthode de régulation de la formation d'ostéoclastes WO2002024228A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001288094A AU2001288094A1 (en) 2000-09-21 2001-09-21 Method of regulating osteoclast formation
JP2002528298A JPWO2002024228A1 (ja) 2000-09-21 2001-09-21 破骨細胞形成を制御する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000286353 2000-09-21
JP2000-286353 2000-09-21

Publications (1)

Publication Number Publication Date
WO2002024228A1 true WO2002024228A1 (fr) 2002-03-28

Family

ID=18770289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008244 WO2002024228A1 (fr) 2000-09-21 2001-09-21 Méthode de régulation de la formation d'ostéoclastes

Country Status (3)

Country Link
JP (1) JPWO2002024228A1 (fr)
AU (1) AU2001288094A1 (fr)
WO (1) WO2002024228A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067974A1 (fr) * 2004-01-19 2005-07-28 Orient Cancer Therapy Co., Ltd. Medicament pour reguler les metastases du cancer sur les os
WO2006068133A1 (fr) * 2004-12-21 2006-06-29 National University Corporation NARA Institute of Science and Technology Procede de suppression de l’expression de nfat2
CN105759053A (zh) * 2016-03-18 2016-07-13 中国人民解放军第四军医大学 一种用于骨质疏松症早期预测的试剂盒
US11639935B2 (en) 2012-02-03 2023-05-02 Charité Universitatsmedizin Berlin CD8+T-cell subsets as markers for prediction of delayed fracture healing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203580A2 (fr) * 1985-05-30 1986-12-03 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Gamma-IFN comme agent d'inhibition (d'empêchement) de processus de décomposition des os
JPH07215893A (ja) * 1994-02-04 1995-08-15 Hiroyo Morii 骨量増加剤
WO1997004799A1 (fr) * 1995-07-25 1997-02-13 Toray Industries, Inc. Remede contre les maladies osseuses
WO2000015807A1 (fr) * 1998-09-15 2000-03-23 M & E Biotech A/S Procede de regulation negative de l'activite des ligands d'osteoprotegerine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203580A2 (fr) * 1985-05-30 1986-12-03 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Gamma-IFN comme agent d'inhibition (d'empêchement) de processus de décomposition des os
JPH07215893A (ja) * 1994-02-04 1995-08-15 Hiroyo Morii 骨量増加剤
WO1997004799A1 (fr) * 1995-07-25 1997-02-13 Toray Industries, Inc. Remede contre les maladies osseuses
WO2000015807A1 (fr) * 1998-09-15 2000-03-23 M & E Biotech A/S Procede de regulation negative de l'activite des ligands d'osteoprotegerine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 134:146299 *
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 134:15660 *
GALIBERT L. ET AL.: "The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily", J. BIOL. CHEM., vol. 273, no. 51, 1998, pages 34120 - 34127, XP002907420 *
NAKASHIMA T. ET AL.: "Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 275, no. 3, 7 September 2000 (2000-09-07), pages 768 - 775, XP002907419 *
TAKAYANAGI HIROSHI ET AL.: "T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma", NATURE, vol. 408, no. 6812, 30 November 2000 (2000-11-30), LONDON, pages 600 - 605, XP002907421 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067974A1 (fr) * 2004-01-19 2005-07-28 Orient Cancer Therapy Co., Ltd. Medicament pour reguler les metastases du cancer sur les os
WO2006068133A1 (fr) * 2004-12-21 2006-06-29 National University Corporation NARA Institute of Science and Technology Procede de suppression de l’expression de nfat2
US11639935B2 (en) 2012-02-03 2023-05-02 Charité Universitatsmedizin Berlin CD8+T-cell subsets as markers for prediction of delayed fracture healing
CN105759053A (zh) * 2016-03-18 2016-07-13 中国人民解放军第四军医大学 一种用于骨质疏松症早期预测的试剂盒

Also Published As

Publication number Publication date
JPWO2002024228A1 (ja) 2004-01-29
AU2001288094A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
AU8979298A (en) Acidic drink
TW200602073A (en) Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a DPP-IV mediated condition
EP1273298A3 (fr) Ritonavir en combinaison avec un inhibiteur de la protéase du VIH additionnel pour le traitement du SIDA
WO2003060465A3 (fr) Compositions, kits et procedes d'identification, d'evaluation, de prevention et de traitement de l'arthrite rhumatoide
AU2003219934A1 (en) Method of treatment or prevention of obesity
EP1769791A3 (fr) Strategies therapeutiques pour la prevention et le traitement de la maladie d'alzheimer
WO2002009814A3 (fr) Nouvelle application d'inhibiteurs de lipase
JO2604B1 (en) Pyrrolidone derivatives as MAOB inhibitors
WO2003084560A3 (fr) Utilisation de l'osteoprotegerine dans le traitement et/ou la prevention des fibroses
WO2003037368A3 (fr) Inhibiteurs smad7 utilises dans le traitement de maladies cns
WO2001064889A3 (fr) CONCEPTION ET DECOUVERTE DE VARIANTS DU TNF-α A BASE DE PROTEINES DESTINES AU TRAITEMENT DES PATHOLOGIES LIEES AU TNF-$g(a)
WO2003078430A8 (fr) Amides d'acide acetique et propionique
WO2002005848A3 (fr) Utilisation d'inhibiteurs de cox-2 pour le traitement et la prevention de troubles oculaires a mediation cox-2
WO2002024228A1 (fr) Méthode de régulation de la formation d'ostéoclastes
EP1099442A3 (fr) Méthodes d'administration d'inhibiteurs de apo B-sécrétion/MTP
IL125375A0 (en) Control of healing process
WO2002024229A1 (fr) Methode de regulation de la formation d'osteoclastes
EP1152762B8 (fr) Utilisation de desoxypeganine dans le traitement de la demence d'alzheimer
WO2002028433A3 (fr) Medicaments
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
WO2001010893A3 (fr) Antagonistes de l'interleukine-16
WO2005047278A3 (fr) Dihydroquinazolines ii substituees
WO1997024138A3 (fr) Utilisation medicale de proteases
AU2002317877A1 (en) Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
WO2004012732A3 (fr) Utilisation d'un inhibiteur du proteasome dans le traitement du dysfonctionnement endothelial et/ou dans le cadre d'une therapie a base de proteasome a faible dose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002528298

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase